Objective: The objective of the research is to investigate the effects of Huangkui capsule on
the expression of SPARC in the kidney tissues of diabetic nephropathy.
Methods: SD rats were divided into three groups: normal control group, untreated DN group and
HKC-treated DN group. The therapeutic effects and underlying molecular mechanism of HKC on DN
rats induced by streptozotocin were evaluated by the levels of serum creatinine, blood urea nitrogen,
24-hour urinary protein and the expression of SPARC. Pathological changes in kidney tissues were
observed through hematoxylin-eosin (HE) staining. Moreover, western blot and quantitative real-time
polymerase chain reaction (qRT-PCR) were applied to detect the variation of SPARC.
Results: This study was performed to investigate the effects of HKC on DN in SD rats model and its
molecular mechanism. Our results showed that the rats treated with HKC had an improved general
state and reduced creatinine, blood urea nitrogen and 24-hour urinary protein levels. The deterioration
of renal function was delayed due to treatment with HKC. HE staining was utilized to observe that
HKC can improve histopathological findings in the kidney tissues of DN rats, including kidney fibrosis.
Results of western blot and qRT-PCR showed that HKC can inhibit the expressions of SPARC in
the rat model of DN.
Conclusion: The present findings demonstrated that HKC inhibited SPARC level and had significant
therapeutic effects on DN.